SCHEMBL10244976

SCHEMBL10244976

CCCOc1ccc(C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)B(O)O)[C@@H](C)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.57
TAS1R1 Q7RTX1 1/20 0.57
PPARG P37231 3/20 0.50
PSMB5 P28074 7/20 0.49
PSMB1 P20618 2/20 0.49
PSMB8 P28062 2/20 0.49
PSMB9 P28065 2/20 0.49
PSMB10 P40306 2/20 0.49
PSMB2 P49721 2/20 0.49
ELANE P08246 1/20 0.49
CTSG P08311 1/20 0.49
CYP3A4 P08684 1/20 0.49
CMA1 P23946 1/20 0.49
PPARA Q07869 1/20 0.49
PLK1 P53350 1/20 0.48
PSMB11 A5LHX3 1/20 0.46
PSMA7 O14818 1/20 0.46
PSMA1 P25786 1/20 0.46
PSMA2 P25787 1/20 0.46
PSMA3 P25788 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3164337 0.88 PSMB5 (0.51) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL3159944 0.83 PSMB5 (0.58) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL8296139 0.81 PSMB5 (0.51) TAS1R3TAS1R1PSMB5PSMB1PSMB8
SCHEMBL3164355 0.80 PSMB5 (0.67) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL3170541 0.78 PSMB5 (0.59) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL10243732 0.76 PSMB5 (0.52) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL10243684 0.76 ALDH1A1 (0.54) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL10243766 0.74 PSMB5 (0.55) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL4157979 0.74 TAS1R3 (0.79) TAS1R3TAS1R1PPARGPPARAPLK1
SCHEMBL19781326 0.74 PPARG (0.83) TAS1R3TAS1R1PPARGPPARAPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-8058262-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-11-15 US disclosed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 TAS1R3 4754/4885TAS1R1 4724/4885PPARG 3927/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 TAS1R3 4754/4885TAS1R1 4724/4885PPARG 3927/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 TAS1R3 4754/4885TAS1R1 4724/4885PPARG 3927/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 TAS1R3 4754/4885TAS1R1 4724/4885PPARG 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.